Literature DB >> 16115035

Eplerenone reduces oxidative stress and enhances eNOS in SHR: vascular functional and structural consequences.

David Sanz-Rosa1, M Pilar Oubiña, Eva Cediel, Natalia De las Heras, Paloma Aragoncillo, Gloria Balfagón, Victoria Cachofeiro, Vicente Lahera.   

Abstract

The aim of the present study was to evaluate the effect of the aldosterone receptor antagonist eplerenone on endothelial function, oxidative stress, and structural alterations present in spontaneously hypertensive rats (SHR). To carry out the study, male SHR (18 weeks old) were treated with two doses of eplerenone (30 and 100 mg/kg/day) for 10 weeks. A group of n = 8 untreated SHR was used as a control-vehicle group, and a group of Wistar Kyoto rats (n = 8) was used as a reference of normotensive conditions. Systolic arterial pressure (SAP) was measured by the tail-cuff method. Endothelium-dependent and -independent relaxations, as well as endothelial nitric oxide synthase (eNOS) and the subunit p22phox of NAD(P)H oxidase mRNA expressions, were studied in aorta from SHR untreated or treated with eplerenone. Media/lumen ratio was also calculated in aortic preparations. In addition, levels of reduced glutathione (GSH), oxidized glutathione (GSSG), and malonyl dialdehyde (MDA) were evaluated in liver homogenates. Treatment with eplerenone reduced (p < 0.05) SAP and normalized aortic media/lumen ratio and acetylcholine relaxations. Both doses of the drug enhanced (p < 0.05) eNOS and reduced p22phox mRNA expressions. Similarly, eplerenone increased (p < 0.05) hepatic GSH/GSSG ratio, and reduced (p < 0.05) hepatic MDA levels in a comparable manner. Consequently, it could be concluded that aldosterone participates in the functional and structural vascular alterations of SHR through the diminution of nitric oxide availability and an enhancement of vascular and systemic oxidative stress.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16115035     DOI: 10.1089/ars.2005.7.1294

Source DB:  PubMed          Journal:  Antioxid Redox Signal        ISSN: 1523-0864            Impact factor:   8.401


  16 in total

1.  Mineralocorticoid Antagonism and Vascular Function in Early Autosomal Dominant Polycystic Kidney Disease: A Randomized Controlled Trial.

Authors:  Kristen L Nowak; Berenice Gitomer; Heather Farmer-Bailey; Wei Wang; Mikaela Malaczewski; Jelena Klawitter; Zhiying You; Diana George; Nayana Patel; Anna Jovanovich; Michel Chonchol
Journal:  Am J Kidney Dis       Date:  2019-02-23       Impact factor: 8.860

Review 2.  Mineralocorticoid receptors in vascular function and disease.

Authors:  Amy McCurley; Iris Z Jaffe
Journal:  Mol Cell Endocrinol       Date:  2011-06-24       Impact factor: 4.102

3.  Effect of aldosterone-producing adenoma on endothelial function and Rho-associated kinase activity in patients with primary aldosteronism.

Authors:  Takeshi Matsumoto; Kenji Oki; Masato Kajikawa; Ayumu Nakashima; Tatsuya Maruhashi; Yumiko Iwamoto; Akimichi Iwamoto; Nozomu Oda; Takayuki Hidaka; Yasuki Kihara; Nobuoki Kohno; Kazuaki Chayama; Chikara Goto; Yoshiki Aibara; Kensuke Noma; James K Liao; Yukihito Higashi
Journal:  Hypertension       Date:  2015-01-26       Impact factor: 10.190

Review 4.  Current therapeutic strategies to mitigate the eNOS dysfunction in ischaemic stroke.

Authors:  Kirtiman Srivastava; Philip M W Bath; Ulvi Bayraktutan
Journal:  Cell Mol Neurobiol       Date:  2011-12-25       Impact factor: 5.046

Review 5.  Vascular endothelial function and hypertension: insights and directions.

Authors:  Kodlipet Dharmashankar; Michael E Widlansky
Journal:  Curr Hypertens Rep       Date:  2010-12       Impact factor: 5.369

6.  The role of mineralocorticoid receptor expression in brain remodeling after cerebral ischemia.

Authors:  Naofumi Oyamada; Masakatsu Sone; Kazutoshi Miyashita; Kwijun Park; Daisuke Taura; Megumi Inuzuka; Takuhiro Sonoyama; Hirokazu Tsujimoto; Yasutomo Fukunaga; Naohisa Tamura; Hiroshi Itoh; Kazuwa Nakao
Journal:  Endocrinology       Date:  2008-04-24       Impact factor: 4.736

7.  Angiotensin and mineralocorticoid receptor antagonism attenuates cardiac oxidative stress in angiotensin II-infused rats.

Authors:  Jacqueline N Minas; Max A Thorwald; Debra Conte; Jose-Pablo Vázquez-Medina; Akira Nishiyama; Rudy M Ortiz
Journal:  Clin Exp Pharmacol Physiol       Date:  2015-11       Impact factor: 2.557

Review 8.  Smooth muscle cell mineralocorticoid receptors: role in vascular function and contribution to cardiovascular disease.

Authors:  Amy McCurley; Adam McGraw; Dafina Pruthi; Iris Z Jaffe
Journal:  Pflugers Arch       Date:  2013-05-01       Impact factor: 3.657

Review 9.  Mineralocorticoid receptor antagonists and endothelial function.

Authors:  Bradley A Maron; Jane A Leopold
Journal:  Curr Opin Investig Drugs       Date:  2008-09

Review 10.  Aldosterone affects blood flow and vascular tone regulated by endothelium-derived NO: therapeutic implications.

Authors:  Noboru Toda; Sadanobu Nakanishi; Shinichi Tanabe
Journal:  Br J Pharmacol       Date:  2013-02       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.